---

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Transaction Summary

• Completed a $100M IPO in 2014
• Lead product, abicipar, started pivotal Phase III clinical trials for AMD - leading cause of blindness

• Zurich-Schlieren, Switzerland
• SIX: MOLN


• Contact:
  Petri Vainio
  
• www.molecularpartners.com
• IPO

Related News

• Abicipar Phase 3 Data Presented at AAO Conference in Chicago:
• Molecular Partners and Astra Zeneca Announce Collaboration
• Molecular Partners’ Partner Allergan Exercises Options for Two DARPin Product Candidates
• Bill Burns Nominated for Election to Molecular Partners’ Board of Directors